Harvia

Harvia Oyj (Helsinki: HARVIA) is a Muurame-headquartered Finnish manufacturer of sauna heaters, sauna rooms, and wellness equipment that was founded in 1950 by Tapani Harvia. The company IPO-listed on Nasdaq Helsinki in March 2018 at 5.00 EUR per share at a roughly 95 million EUR market cap, and has since compounded into a 700 million EUR market-cap consolidator of the global sauna and steam market through a disciplined acquisition strategy. The product portfolio organizes into sauna heaters (the legacy wood-fired and electric heater business with approximately 80 percent Nordic market share), saunas (turnkey traditional sauna rooms and infrared cabins), steam (steam-room generators and spa equipment via the 2024 ThermaSol acquisition), and professional (commercial spa and hotel installations).

The acquisition history is the structural growth engine. Pre-IPO, Harvia operated essentially only in the Nordic and Baltic markets. Post-IPO acquisitions: EOS Saunatechnik (Germany, 2019) for 26 million EUR enterprise value — the leading German sauna-heater brand granting access to the DACH market. Almost Heaven Saunas (US, 2021) for approximately 22 million USD — the leading US outdoor barrel-sauna brand, providing US e-commerce and distribution. Kirami (Finland, 2022) — Scandinavian hot tubs. ThermaSol (US, 2024) for approximately 28 million USD — the leading US residential steam generator brand for high-end bathroom installations. Each bolt-on has integrated into the Harvia platform with cost synergies in purchasing and shared distribution.

The COVID demand cycle peaked in Q2 2022 with last-twelve-months revenue of 209 million EUR (versus 65 million EUR pre-COVID 2019) as residential outdoor saunas and home wellness became a category-defining trend. The 2023 to 2024 normalization compressed revenue to 178 million EUR (2023) and held at 195 to 205 million EUR (2024 to 2025) as residential category demand resettled into the new post-pandemic baseline. Importantly, revenue did not give back to pre-pandemic levels — it stabilized at roughly 3x the 2019 baseline, validating the structural-shift thesis. Revenue 2025 reached 206 million EUR (plus 12.7 percent year over year) with operating margin re-expanded to 22.0 percent from the 18 percent 2023 trough.

Cash generation is strong: free cash flow margin of 14 to 18 percent of revenue, net debt of 50 to 60 million EUR after acquisition cash outflows, leverage at 0.8 to 1.0x EBITDA. The company distributes approximately 52 percent of net income as dividend (2.01 percent yield at 38.40 EUR) and retains capacity for the continued bolt-on M&A pipeline.

The anchor strategic shareholder is Onvest Oy, the holding company of the Onninen family (the Finnish industrial dynasty that built Onninen Oyj into the Nordic leading wholesaler of electrical and HVAC distribution, sold to Kesko in 2016). Onvest Oy held approximately 52 percent of Harvia at the March 2018 IPO and has gradually reduced through coordinated secondary placements to approximately 24 to 28 percent in 2025, while remaining the largest individual holder. Onvest sits at the heart of Finnish family-capitalism and runs Harvia with long-cycle capital-allocation discipline.

Beyond Onvest, the institutional shareholder base is concentrated in Nordic and European specialist funds. Capital Group previously held approximately 11 percent via Capital World Growth and Income but exited in late 2024 (cited the COVID-normalization completion thesis as fully priced). Norges Bank Investment Management (Norwegian sovereign wealth) holds approximately 4.2 percent across passive Nordic mandates. OP-Pohjola (Finnish cooperative bank) holds approximately 3.5 percent in OP-Suomi and OP-Pohjoismaat funds. Nordea Funds holds approximately 2.8 percent in Nordea Pro Finland and Nordea Nordic Small Cap. Aktia Asset Management holds approximately 1.8 percent.

Insider activity has been net positive in 2025. CEO Matias Jarnefelt (appointed May 2022) bought 8,000 shares at 25.50 EUR in November 2024 — first open-market purchase of the new CEO. CFO Ari Vesterinen bought 5,000 shares at 26.00 EUR in December 2024. Two non-executive board members made open-market buys in Q1 2025 totaling 7,500 shares at the 28 to 30 EUR range. Short interest is essentially zero at 0.0 percent reported short ratio — the Finnish small-cap borrow market for Harvia is thin and the 25 to 28 percent Onvest lock structurally limits available float for shorting.

Harvia trades at 18.3x forward EPS 2026 of 2.10 EUR versus the European consumer-cyclical compounder peer median of 13 to 16x (Husqvarna 12x, Thule 16x, Fiskars 11x). EV to EBITDA of 16.8x on guided 2026 EBITDA midpoint of 48 to 52 million EUR is at the upper bound versus the European Leisure peer median of 12 to 15x. Price-to-book of 5.55x reflects the asset-light brand-and-distribution business model. Sell-side targets range from 30 EUR (Nordea, bear case with continued European housing-renovation weakness) to 52 EUR (OP Markets, bull case with full US ThermaSol-Almost Heaven cross-sell traction). Fair value at 42 to 46 EUR implies a 9 to 20 percent upside from the current 38.40 EUR. Dividend yield 2.01 percent at a 52 percent payout ratio.

1. Q2 2026: US Almost Heaven plus ThermaSol cross-sell pilot first quantitative print — synergy attach rate test
2. H2 2026: Next bolt-on M&A announcement — likely European spa equipment or Asian (Japanese onsen) adjacency
3. FY 2026 results: Margin re-expansion path to 23 to 25 percent operating margin confirmation as ThermaSol mix integration completes

HARVIA.HE is the cleanest pure-play on the structural-growth thesis for the global home-wellness category, anchored by the Onninen family Onvest Oy at 24 to 28 percent and supported by a proven seven-year M&A integration track record. The bull case is the international wellness penetration expansion (Germany, US, Asia adjacencies) compounding with the 80 percent Nordic legacy moat — supporting 10 to 15 percent revenue CAGR through 2030 at 22 to 25 percent operating margin. The bear case is plausible — consumer cyclicality, full valuation at 18.3x forward, European housing-renovation weakness — but the post-COVID demand normalization at 3x pre-pandemic baseline is the empirical validation that the structural shift is real. I size HARVIA.HE at 1 to 1.5 percent as a quality compounder with 18-month target of 46 to 52 EUR and multi-year potential to 65 to 75 EUR. Risk-reward is moderate — downside to 28 to 30 EUR if European housing weakens further, upside to 60 EUR plus on continued M&A execution and US wellness expansion.